Novo Nordisk pays close attention to the payers
Drug companies are forced to consider the increasingly powerful payers in the US when pricing their products. “If we don’t get access to the right patients, our strategy will eventually collapse,” says Jakob Riis, Novo Nordisk’s EVP of China, Pacific & Marketing.
BY BENJAMIN WERNER CHRISTENSEN
Drug companies have to reassure payers that medicine costs will not rapidly increase in the short term, if they want commercial success in the long term, says Jakob Riis, who is EVP, China, Pacific & Marketing for Novo Nordisk, in an interview with MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches obesity drug in the US
For abonnenter
Novo wins approval of obesity drug in Europe
For abonnenter
